TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
In the first quarter of the year, 245 companies reported a net gain of 14.
 
Author:中国铭铉 企划部  Release Time:2017-5-9 9:43:02  Number Browse:425
 
Medical network - May 9, 245 listed companies released a quarterly in 2017, according to data, the net profit attributable to shareholders of listed companies from a year-on-year increase of 175, 28 companies which belong to the female net income increased by more than 50%; Another 70 companies were down from a year earlier. 
 
Net profit of 14 companies doubled 
 
According to Wind data, 245 companies in the pharmaceutical industry have reported quarterly results. Of these, 28 companies reported net profit growth of more than 50 per cent, while 14 companies doubled their net profit. 
 
Dongwu securities believes that overall revenue growth in the sector will rise in the first quarter of 2017, and a rebound in the bottom is expected to accelerate non-net profit growth. In the first quarter of this year, the total operating income of the listed companies in the pharmaceutical industry was 266.98 billion yuan, up by 18.00% year on year. Net profits totaled 218.89 billion yuan, up 7.64 percent year on year. 
 
According to the subdivision, the chemical agents are performing well, and most of the leading companies have met their expectations and maintained steady and fast growth. In the first quarter, total income and non-net income growth were 17.34% and 20.78% respectively. The biopharmaceutical sector did not perform smoothly. In the first quarter of 2017, overall income and non-net income growth were 13.94% and 17.47% respectively. 
 
In the first quarter of this year, the first quarter of the year was 8669.06 yuan, a year-on-year increase of 41.70%. Net income was 2053.73 million yuan, up 387.08 percent year on year, the highest net profit growth in the industry. The main business of the company is the r&d, production and sales of vitamin D3 upstream and downstream series products, and the increase in sales revenue mainly is the increase in sales of the original 25-hydroxy vitamin D3 products. 
 
The Chinese medicine sector faces factors such as health care reform. In the first quarter of 2017, the industry's overall income and net income growth were 11.61 per cent and 17.60 per cent respectively. The increase in sales of related products is under pressure due to the limited use of injectable drugs for most traditional Chinese medicines. Societe generale securities believes that the next big variety in the field of TCM injections in the charged fees under the influence of growth may continue, at the same time, under the background of countries to support the development of Chinese medicine, Chinese medicine fields such as traditional Chinese medicine (TCM) consumer goods, part of the oral Chinese patent medicine, children's college medicine, including traditional Chinese medicine yinpian, traditional Chinese medicine formula particles, fine traditional Chinese medicines, such as market segment, and seat in the field of medicine of traditional Chinese medicine, the national physician pavilion and other new forms are expected to obtain structural development opportunities. 
 
The pharmaceutical business sector was robust 
 
Influenced by tax and industry policies, pharmaceutical business has become the healthiest medicine sub-industry for industry consolidation. Overall performance in the first quarter of 2017, medicine, electricity to maintain the high speed growth, the overall income and deduct the net profit growth of 21.06% and 40.66% respectively, rose 2.74% and 16.09%. 
 
The rui kang pharmaceutical business income is 4.979 billion yuan in the first quarter, year-on-year growth of 53.50%, net profit attributable to shareholders of listed companies of 292 million yuan, up 241.72%; In the first quarter of this year, the company's operating income was 188.14 billion yuan, up 21.80 percent year on year, and the net profit attributable to the listed company's shareholders was 1.86 billion yuan, up 31.31 percent year on year. In the first quarter, the average income of the people was 17.29 billion yuan, up 30.08% year on year, and the net profit attributable to the listed company's shareholders was 11.3 billion yuan, up 43.33% year on year. 
 
For the quarter. Rui kang pharmaceutical, said first-quarter earnings growth bigger reason is that business has grown steadily in the province, fujian association of foreign languages and rapid business development, accounts receivable bad debts provision ratio changes. Kyushu tong said that the main reason is that during the reporting period the company core business, proprietary Chinese medicine, western medicine and hospital pure pin, medical devices and consumer products such as strategic business growth. Shanghai securities research report that, kyushu pure sales revenue growth is higher than that of allocating business, such as "two votes" policy continues to advance, pure pin business income proportion will continue to improve, considering the gross profit margin is higher than pure pin business transfers business, the company has a perfect marketing network, terminal cover ability and competitive advantage, the company's overall profitability is expected to continue to improve. 
 
The people's first-quarter revenue came mainly from the increase in the number of stores and the increase in sales of goods. 
 
Previous article:How do you spend more than $1 billion a year on these 16 drug companies
Next article:We supported the medical and medical devices for rehabilitation and care, and the implementation of the guidelines in 29 provinces
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号